Abstract Presenter Title
S138 Jesus G. Berdeja Update on bb2121, a promising therapy for patients
with heavily pre-treated relapsed/refractory
multiple myeloma
S110 Olivier Casasnovas AHL2011: Outstanding disease control with a
minimized BEACOPP exposure and toxicity in
patients with advanced Hodgkin lymphoma
S149 Fang Liu First-in-Human CLL1-CD33 Compound CAR T Cells as a
Two-pronged Approach for the treatment of
refractory acute myeloid leukemia
S151 Valentin Goede Overall survival benefit of obinutuzumab over
rituximab when combined with chlorambucil in
patients with chronic lymphocytic leukemia and
comorbidities
S154 Frank Morschhauser Is RELEVANCE Relevant? Results of the phase III
study of R2 vs R-chemo in first-line follicular
lymphoma
S152 Francesca Vinchi Iron: a double-edged sword in inflammation
Abstract Presenter Title
S832 Jing Pan New anti-CD22 CAR-T immunotherapy saved life
of children with leukemia
S852 Meletios iNNOVATE Study: Ibrutinib plus Rituximab for
Dimopoulos Patients with Waldenström’s Macroglobulinemia
S802 Laurie H. Sehn Answering the unmet need in one of the most
common types of lymphoma: It’s as simple as A-D-C
